Background: Management of Crohn's disease (CD) is moving towards the therapeutic goal of mucosal healing using biomarkers of inflammation, faecal calprotectin (FC) and C-reactive protein (CRP), to optimise therapy. CALM demonstrated superior endoscopic outcomes in patients whose treatment was escalated based on a tight control algorithm using symptoms and biomarkers than in patients managed conventionally, 1 but the optimal biomarker cut-offs to predict mucosal healing have not been established. In this analysis from CALM, association of endoscopic outcomes with FC and CRP cutoffs was investigated. Methods: Adult patients with CD (N = 244) were assessed for association of mucosal healing (CD Endoscopic Index of Severity [CDEIS] < 4) and no deep ulcers (primary endpoint in CALM) and endoscopic response (CDEIS decrease >5 from baseline [BL]) with levels of FC and CRP at 48 weeks using Chi-square test. Analysed cut-offs for FC (<250 or ≥250 µg/g) and CRP (<5 or ≥5 mg/l) at 48 weeks were based on criteria for treatment escalation in the tight control group. Data are summarised as observed in patients with both endoscopic outcome and biomarker level.
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Results: Association between the two endoscopic endpoints and CRP and FC cut-offs at 48 weeks is shown in Table. Significantly greater proportions of patients with CRP concentrations of <5 mg/l achieved endoscopic outcomes in CALM. Similar findings, to a greater extent, were associated with FC <250 μg/g. Even higher proportion of patients achieved the two endoscopic endpoints when both CRP and FC were considered. Conclusions: Correlation of biomarker cut-offs with endoscopic outcomes is an important finding for future management of CD. Additional studies are needed to further define the biomarker cut-offs. 
